CA3003559C - Fused thiazolopyrimidine derivatives as mnks inhibitors - Google Patents

Fused thiazolopyrimidine derivatives as mnks inhibitors

Info

Publication number
CA3003559C
CA3003559C CA3003559A CA3003559A CA3003559C CA 3003559 C CA3003559 C CA 3003559C CA 3003559 A CA3003559 A CA 3003559A CA 3003559 A CA3003559 A CA 3003559A CA 3003559 C CA3003559 C CA 3003559C
Authority
CA
Canada
Prior art keywords
nmr
mhz
ppm
compound according
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3003559A
Other languages
English (en)
French (fr)
Other versions
CA3003559A1 (en
Inventor
Jon James WINTER-HOLT
Edward Giles McIver
Martin Ambler
Stephen Lewis
Joanne Osborne
Kayleigh Webb-Smith
Original Assignee
LifeArc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LifeArc filed Critical LifeArc
Priority to CA3240011A priority Critical patent/CA3240011A1/en
Publication of CA3003559A1 publication Critical patent/CA3003559A1/en
Application granted granted Critical
Publication of CA3003559C publication Critical patent/CA3003559C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3003559A 2015-11-20 2016-11-16 Fused thiazolopyrimidine derivatives as mnks inhibitors Active CA3003559C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3240011A CA3240011A1 (en) 2015-11-20 2016-11-16 Fused thiazolopyrimidine derivatives as mnks inhibitors

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1520500.8A GB201520500D0 (en) 2015-11-20 2015-11-20 Compounds
GB1520500.8 2015-11-20
PCT/GB2016/053580 WO2017085484A1 (en) 2015-11-20 2016-11-16 Fused thiazolopyrimidine derivatives as mnks inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3240011A Division CA3240011A1 (en) 2015-11-20 2016-11-16 Fused thiazolopyrimidine derivatives as mnks inhibitors

Publications (2)

Publication Number Publication Date
CA3003559A1 CA3003559A1 (en) 2017-05-26
CA3003559C true CA3003559C (en) 2024-09-10

Family

ID=55133106

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3003559A Active CA3003559C (en) 2015-11-20 2016-11-16 Fused thiazolopyrimidine derivatives as mnks inhibitors
CA3240011A Pending CA3240011A1 (en) 2015-11-20 2016-11-16 Fused thiazolopyrimidine derivatives as mnks inhibitors

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA3240011A Pending CA3240011A1 (en) 2015-11-20 2016-11-16 Fused thiazolopyrimidine derivatives as mnks inhibitors

Country Status (9)

Country Link
US (2) US10669284B2 (enExample)
EP (2) EP3377501B1 (enExample)
JP (2) JP6928605B2 (enExample)
CN (1) CN108495855B (enExample)
AU (1) AU2016355104B2 (enExample)
CA (2) CA3003559C (enExample)
ES (2) ES2893154T3 (enExample)
GB (1) GB201520500D0 (enExample)
WO (1) WO2017085484A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI713455B (zh) 2014-06-25 2020-12-21 美商伊凡克特治療公司 ＭｎＫ抑制劑及其相關方法
DK3582776T3 (da) 2017-02-14 2024-01-08 Effector Therapeutics Inc Piperidinsubstituerede mnk-hæmmere og dertil relaterede fremgangsmåder
CN109020957B (zh) * 2017-06-12 2023-01-13 南京天印健华医药科技有限公司 作为mnk抑制剂的杂环化合物
KR20210102211A (ko) 2018-10-24 2021-08-19 이펙터 테라퓨틱스, 인크. Mnk 억제제의 결정질 형태
CN110903286B (zh) * 2019-12-16 2021-09-24 沈阳药科大学 4,6-双取代吡啶[3,2-d]嘧啶类化合物及其制备和应用
AU2021300363A1 (en) * 2020-06-30 2023-02-09 4E Therapeutics, Inc. Pyridine-1,5-diones exhibiting MNK inhibition and their method of use
CN118146134A (zh) * 2024-02-07 2024-06-07 南方海洋科学与工程广东省实验室(湛江) 一种3-羟基吡咯烷衍生物及其制备方法与应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
US20050239806A1 (en) 2004-01-13 2005-10-27 Ambit Biosciences Corporation Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases
TW200538120A (en) 2004-02-20 2005-12-01 Kirin Brewery Compound having TGF-beta inhibitory activity and pharmaceutical composition containing same
EP1731523A4 (en) 2004-04-01 2009-08-12 Takeda Pharmaceutical THIAZOLOPYRIMIDINDERIVAT
WO2006014325A2 (en) 2004-07-02 2006-02-09 Exelixis, Inc. C-met modulators and method of use
JP5302883B2 (ja) 2006-04-07 2013-10-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 医薬組成物用のｍｎｋ１／ｍｎｋ２阻害活性を有するチエノピリミジン
EP1889847A1 (en) 2006-07-10 2008-02-20 DeveloGen Aktiengesellschaft Pyrrolopyrimidines for pharmaceutical compositions
WO2008057402A2 (en) * 2006-11-02 2008-05-15 Cytovia, Inc. N-aryl-isoxazolopyrimidin-4-amines and related compounds as activators of caspases and inducers of apoptosis and the use thereof
US20100247517A1 (en) * 2007-11-22 2010-09-30 Boehringer Ingelheim Internationational GmbH Use of mnk inhibitors for the treatment of alzheimer's disease
WO2010023181A1 (en) * 2008-08-26 2010-03-04 Boehringer Ingelheim International Gmbh Thienopyrimidines for pharmaceutical compositions
MX2012009735A (es) 2010-02-26 2012-09-12 Boehringer Ingelheim Int 4-[cicloalquiloxi (hetero) arilamino] tieno [2,3-d] pirimidinas que tienen actividad inhibitoria de mnk1/mnk2 para composiciones farmaceuticas.
UY33241A (es) 2010-02-26 2011-09-30 Boehringer Ingelheim Int ?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?.
BR112012021453A2 (pt) * 2010-02-26 2017-02-21 Boehringer Ingelheim Int tienopirimidina, sua composição farmacêutica e seu uso
CN102002044A (zh) * 2010-09-29 2011-04-06 中国药科大学 嘌呤-8-酮类及噻唑并嘧啶类衍生物及其制备方法和医药用途
JP2016506944A (ja) 2013-02-01 2016-03-07 バイエル・ファルマ・アクティエンゲゼルシャフト 置換ピラゾロピリミジニルアミノ−インダゾール
US9675612B2 (en) * 2013-03-06 2017-06-13 Bayer Pharma Aktiengesellschaft Substituted thiazolopyrimidines
JP2016527216A (ja) * 2013-07-08 2016-09-08 バイエル・ファルマ・アクティエンゲゼルシャフト 置換ピラゾロピリジン

Also Published As

Publication number Publication date
EP3939981B1 (en) 2024-04-03
GB201520500D0 (en) 2016-01-06
EP3377501A1 (en) 2018-09-26
JP6928605B2 (ja) 2021-09-01
CN108495855B (zh) 2022-05-31
EP3377501B1 (en) 2021-08-18
WO2017085484A1 (en) 2017-05-26
US20200247822A1 (en) 2020-08-06
US10669284B2 (en) 2020-06-02
ES2893154T3 (es) 2022-02-08
US11136338B2 (en) 2021-10-05
JP7181647B2 (ja) 2022-12-01
CN108495855A (zh) 2018-09-04
HK1253575A1 (en) 2019-06-21
CA3240011A1 (en) 2017-05-26
EP3939981A1 (en) 2022-01-19
US20180346483A1 (en) 2018-12-06
AU2016355104A1 (en) 2018-05-24
ES2981048T3 (es) 2024-10-07
CA3003559A1 (en) 2017-05-26
EP3939981C0 (en) 2024-04-03
JP2021073306A (ja) 2021-05-13
AU2016355104B2 (en) 2021-01-28
JP2018534314A (ja) 2018-11-22

Similar Documents

Publication Publication Date Title
CA3003559C (en) Fused thiazolopyrimidine derivatives as mnks inhibitors
CN104903321B (zh) 作为激酶抑制剂的经取代三环苯并咪唑
EP3679026A1 (en) Glutarimide
JP6914933B2 (ja) ヤヌスキナーゼ、並びにその組成物及びその使用
AU2016293441A1 (en) Indazole and azaindazole compounds as IRAK-4 inhibitors
KR20200083543A (ko) 디아자스피로 rock 억제제
CN103370314A (zh) 作为用于治疗癌症疾病的fgfr激酶抑制剂的取代苯并吡嗪衍生物
KR20240062147A (ko) P53의 돌연변이체를 표적으로 하는 화합물
CN106456580A (zh) 作为蛋白质脱乙酰酶抑制剂和蛋白质脱乙酰酶‑蛋白质激酶双重抑制剂的杂环异羟肟酸及其使用方法
CA3003554C (en) Pyrropyrimidine compounds as mnks inhibitors
CN108017633A (zh) N-[5-(嘧啶-2-氨基)-2,4-二取代苯基]-2-氟代丙烯酰胺衍生物及应用
HK40065647B (en) Fused thiazolopyrimidine derivatives as mnks inhibitors
HK40065647A (en) Fused thiazolopyrimidine derivatives as mnks inhibitors
Webb-Smith 2) Patent Application Publication o Pub. No.: US 2020/0247822 A1
HK1253575B (en) Fused thiazolopyrimidine derivatives as mnks inhibitors
WO2022028556A1 (zh) Cdk9抑制剂及其用途
HK40037886B (en) Pyrropyrimidine compounds as mnks inhibitors
HK1253576B (en) Pyrropyrimidine compounds as mnks inhibitors
HK1229722A1 (en) Heterocyclic hydroxamic acids as protein deacetylase inhibitors and dual protein deacetylase-protein kinase inhibitors and methods of use thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210917

EEER Examination request

Effective date: 20210917

EEER Examination request

Effective date: 20210917

EEER Examination request

Effective date: 20210917

EEER Examination request

Effective date: 20210917

EEER Examination request

Effective date: 20210917

EEER Examination request

Effective date: 20210917

EEER Examination request

Effective date: 20210917

EEER Examination request

Effective date: 20210917

EEER Examination request

Effective date: 20210917

EEER Examination request

Effective date: 20210917

EEER Examination request

Effective date: 20210917